By Fineline Cube 
Jacobio Pharmaceuticals (HKG: 1167) today announced a capital‑increase and equity‑transfer agreement that will see Shanxi Oceanpine Management Consulting Partnership (Limited Partnership) acquire an 80 % stake in Beijing Jacoray Pharmaceutical Technology Co., Ltd. (Jacoray). The deal is part of Jacobio’s strategy to concentrate resources on its core oncology pipeline, including its Pan‑KRAS inhibitors and iADC platform.
Transaction Highlights
| Item | Detail |
|---|---|
| Acquiring Party | Oceanpine Capital |
| Target Company | Jacoray – a subsidiary of Beijing Jacobio |
| Equity Split Post‑Transaction | Beijing Jacobio 10 %, Oceanpine Capital 80 %, Industrial Cooperation Partner 10 % |
| Initial Payment | RMB 125 million |
| Milestone Payments | RMB 75 million (subject to performance milestones) |
| Use of Proceeds | Research, development, manufacturing and commercialization of Pan‑KRAS inhibitors and other oncology assets |
| Strategic Rationale | Frees up capital for Jacobio’s oncology focus; aligns with early‑stage cardiovascular work at Jincoricon |
Strategic Context
- Oncology Focus – Jacobio’s flagship programs include KRAS‑targeted therapies and the iADC platform. The capital injection will accelerate the clinical development of its Pan‑KRAS inhibitors, a key growth driver for the company.
- Platform Synergies – The transaction also supports Jacobio’s broader innovation strategy, leveraging Jacoray’s manufacturing capabilities to scale new oncology molecules.
- Partnership Value – Oceanpine Capital brings deep expertise in drug development financing, while the industrial partner contributes complementary technology assets, creating a balanced 10‑80‑10 equity structure.
Market Implications
The deal positions Jacobio to deepen its oncology pipeline while maintaining a lean balance sheet. Investors should monitor milestone achievements tied to the RMB 75 million payment schedule, as these will dictate the timing of further capital infusions.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech